150 related articles for article (PubMed ID: 38260049)
1. The effect of daily oral PrEP use during pregnancy on bone mineral density among adolescent girls and young women in Uganda.
Zewdie K; Kiweewa FM; Ssebuliba T; Morrison SA; Muwonge TR; Boyer J; Bambia F; Badaru J; Stein G; Mugwanya KK; Wyatt C; Yin MT; Mujugira A; Heffron R
Front Reprod Health; 2023; 5():1240990. PubMed ID: 38260049
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda.
Kiweewa Matovu F; Kiwanuka N; Nabwana M; Scholes D; Musoke P; Glenn Fowler M; Beksinska ME; Pettifor JM; Brown TT;
Lancet Glob Health; 2022 May; 10(5):e694-e704. PubMed ID: 35427526
[TBL] [Abstract][Full Text] [Related]
3. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
[TBL] [Abstract][Full Text] [Related]
4. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
Mirembe BG; Kelly CW; Mgodi N; Greenspan S; Dai JY; Mayo A; Piper J; Akello CA; Kiweewa FM; Magure T; Nakabiito C; Marrazzo JM; Chirenje ZM; Riddler SA;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):287-94. PubMed ID: 26866954
[TBL] [Abstract][Full Text] [Related]
5. Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.
Spinelli MA; Glidden DV; Anderson PL; Gandhi M; McMahan VM; Defechereux P; Schechter M; Veloso VG; Chariyalertsak S; Guanira JV; Bekker LG; Buchbinder SP; Grant RM
AIDS Res Hum Retroviruses; 2019 Sep; 35(9):788-793. PubMed ID: 31119944
[TBL] [Abstract][Full Text] [Related]
6. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa.
Khadka N; Gorbach PM; Nyemba DC; Mvududu R; Mashele N; Javanbakht M; Nianogo RA; Aldrovandi GM; Bekker LG; Coates TJ; Myer L; Joseph Davey DL
Front Reprod Health; 2023; 5():1224474. PubMed ID: 37795521
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
[TBL] [Abstract][Full Text] [Related]
9. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
Pornpaisalsakul K; Songtaweesin WN; Tepmongkol S; Wongharn P; Kawichai S; Suponsilchai V; Anugulruengkitt S; Puthanakit T;
J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
[TBL] [Abstract][Full Text] [Related]
10. Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study.
Joseph Davey D; Nyemba DC; Castillo-Mancilla J; Wiesner L; Norman J; Mvududu R; Mashele N; Johnson LF; Bekker LG; Gorbach P; Coates TJ; Myer L
J Int AIDS Soc; 2022 Dec; 25(12):e26044. PubMed ID: 36480171
[TBL] [Abstract][Full Text] [Related]
11. Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa.
Joseph Davey DL; Mvududu R; Mashele N; Lesosky M; Khadka N; Bekker LG; Gorbach P; Coates TJ; Myer L
J Int AIDS Soc; 2022 Feb; 25(2):e25866. PubMed ID: 35138678
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density, nutrient intake, and physical activity among young women from Uganda.
Heffron R; Muwonge TR; Boyer J; Matovu F; Zia Y; Bagaya M; Ssebuliba T; Morrison S; Bambia F; Nsubuga R; Badaru J; Stein G; Mugwanya KK; Wyatt C; Baeten JM; Yin MT; Mujugira A;
Arch Osteoporos; 2022 Oct; 17(1):134. PubMed ID: 36216962
[TBL] [Abstract][Full Text] [Related]
13. Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers.
Kayesu I; Mayanja Y; Nakirijja C; Machira YW; Price M; Seeley J; Siu G
BMC Womens Health; 2022 Nov; 22(1):440. PubMed ID: 36357920
[TBL] [Abstract][Full Text] [Related]
14. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
15. Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
Brown TT; Yuhas K; Mayer KH; Landovitz RJ; Marzinke MA; Hendrix CW; Chen YQ; Klingman KL; Chege W; Mccauley MB; Gulick RM; Wilkin TJ
J Antimicrob Chemother; 2022 Feb; 77(2):500-506. PubMed ID: 34791296
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers.
Harel Z; Gold M; Cromer B; Bruner A; Stager M; Bachrach L; Wolter K; Reid C; Hertweck P; Nelson A; Nelson D; Coupey S; Johnson C; Burkman R; Bone H
J Adolesc Health; 2007 Jan; 40(1):44-53. PubMed ID: 17185205
[TBL] [Abstract][Full Text] [Related]
17. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
Mayanja Y; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Buzibye A; Omali D; Chinyenze K; Kuteesa M; Kaleebu P; Price MA
J Int AIDS Soc; 2022 May; 25(5):e25909. PubMed ID: 35543110
[TBL] [Abstract][Full Text] [Related]
18. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
Matthews LT; Heffron R; Mugo NR; Cohen CR; Hendrix CW; Celum C; Bangsberg DR; Baeten JM;
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):91-7. PubMed ID: 25118795
[TBL] [Abstract][Full Text] [Related]
19. A Text Messaging-Based Support Intervention to Enhance Pre-exposure Prophylaxis for HIV Prevention Adherence During Pregnancy and Breastfeeding: Protocol for a Randomized Controlled Trial.
Mogaka JN; Otieno FA; Akim E; Beima-Sofie K; Dettinger J; Gomez L; Marwa M; Odhiambo B; Ngure K; Ronen K; Sharma M; John-Stewart G; Richardson B; Stern J; Unger J; Udren J; Watoyi S; Pintye J; Kinuthia J
JMIR Res Protoc; 2023 Jan; 12():e41170. PubMed ID: 36716092
[TBL] [Abstract][Full Text] [Related]
20. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
